During the past decade, Yale University School of Medicine, Department of Neurology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yale University School of Medicine, Department of Neurology" #1 sponsor was "Biogen" with 1 trials, followed by "Columbia University" with 1 trials sponsored, "Grifols Therapeutics LLC" with 1 trials sponsored, "Immunovant Sciences GmbH" with 1 trials sponsored and "Yale University" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yale University School of Medicine, Department of Neurology" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator and "Elan Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Yale University School of Medicine, Department of Neurology" are "Myasthenia Gravis" (3 trials), "Amyotrophic Lateral Sclerosis" (1 trials), "Lou Gehrig's Disease" (1 trials) and "Multiple Sclerosis, Relapsing-Remitting" (1 trials). Many other conditions were trialed in "Yale University School of Medicine, Department of Neurology" in a lesser frequency.

Most popular intervention types in "Yale University School of Medicine, Department of Neurology" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "IGIV-C" (1 trials), "Natalizumab" (1 trials), "RVT-1401" (1 trials) and "Rituximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Yale University School of Medicine, Department of Neurology" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Yale University School of Medicine, Department of Neurology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Yale University School of Medicine, Department of Neurology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Yale University School of Medicine, Department of Neurology, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".